(Q36790208)

16 August 2017

0 references

A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies (English)

1 reference

16 August 2017

0 references

1 reference

Munmun Rahman

1

1 reference

16 August 2017

Kentaro Nakayama

2

1 reference

16 August 2017

Tomoka Ishibashi

3

1 reference

16 August 2017

Masako Ishikawa

4

1 reference

16 August 2017

Mohammed Tanjimur Rahman

5

1 reference

16 August 2017

Hiroshi Katagiri

6

1 reference

16 August 2017

Atsuko Katagiri

7

1 reference

16 August 2017

Kouji Iida

8

1 reference

16 August 2017

Yoshihiro Kikuchi

9

1 reference

16 August 2017

Kohji Miyazaki

10

1 reference

16 August 2017

language of work or name

English

0 references

publication date

15 March 2013

1 reference

International Journal of Molecular Sciences

16 August 2017

1 reference

16 August 2017

14

1 reference

16 August 2017

3

1 reference

16 August 2017

6067-6073

1 reference

Creative Commons Attribution 4.0 International

16 August 2017

start time

15 March 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Current status on biologic therapies in the treatment of epithelial ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634399

Antiangiogenic drugs in ovarian cancer

27 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23502469

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23502469

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3390/IJMS14036067

1 reference

16 August 2017

1 reference

16 August 2017

1 reference